Corine Ekhart

TL;DR: It is indicated that the presently evaluated variant alleles in the CYP2B6, CyP2C9, CYP3A4, CYp3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1 genes do not explain the interindividual variability in cyclophosphamide and 4-hydroxycyclophosphamate pharmacokinetics and are, probably, not the cause of the observed variability in toxicity.

TL;DR: The most important polymorphisms shown to influence survival after cancer treatment are polymorphisms in the genes encoding the phase II detoxification enzymes glutathione-S-transferases, and it appears that GSTM1 null and GSTT1 null have a clear association with longer overall survival in patients with different malignancies who are treated with substrates for these GSTs.

TL;DR: Assessment and characterize sex differences in adverse drug reactions reported to the national pharmacovigilance centre in the Netherlands while considering differences in drug use.

TL;DR: It is suggested that in overweight and obese patients, with a normal renal function, a flat carboplatin dose should be administered, based on the populationcarboplatin clearance (8.38 l/h = 140 mL/min), and in case an AUC of 5 mg min/mL is desired, the appropriate dose for carboplarin would be 5 × 140–= 700 mg.

TL;DR: Patients heterozygous for the ALDH3A1-2 and ALDH1A1*2 allele have an increased risk of haemorrhagic cystitis and liver toxicity, respectively, compared with patients with wild-type alleles when treated with a high-dose chemotherapy combination of CTC.